Iron chelators as mitophagy agents: Potential and limitations

Autor
Babula, Petr
Přibyl, Tomáš
Zelenka, Jaroslav
Ruml, Tomáš
Datum vydání
2024Publikováno v
Biomedicine & PharmacotherapyNakladatel / Místo vydání
ElsevierRočník / Číslo vydání
179 (October)ISBN / ISSN
ISSN: 0753-3322ISBN / ISSN
eISSN: 1950-6007Informace o financování
MSM//SVV260637
MSM//SVV260521
UK//COOP
MSM//LM2023053
TA0//TN02000109
MZ0//NU22-08-00160
MZ0//NU21-08-00407
MSM//LX22NPO5104
MSM//LX22NPO5107
MSM//LX22NPO5102
MV0//VB02000056
Metadata
Zobrazit celý záznamKolekce
Tato publikace má vydavatelskou verzi s DOI 10.1016/j.biopha.2024.117407
Abstrakt
Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
Klíčová slova
Mitophagy, Iron heomeostais, Iron chelators, Cancer, Neurodegenerative diseases, Cardiovascular diseases,
Trvalý odkaz
https://hdl.handle.net/20.500.14178/2690Licence
Licence pro užití plného textu výsledku: Creative Commons Uveďte původ 4.0 International
